tbuckley/cabot-search huggingface dataset:
Doctors’ wellbeing: GMC promises action
Authors: Abi Rimmer
Journal: BMJ (2019)

The General Medical Council has announced that it will work with other NHS organisations to improve doctors’ wellbeing across the UK. The commitment is a response to a review it commissioned last year into the factors contributing to poor wellbeing among medical students and doctors.

The report of the review, Caring for Doctors, Caring for Patients ,1 calls on employers to adopt minimum standards of food and rest facilities, as set out in the BMA’s Fatigue and Facilities charter,2 and to use the BMA and NHS Employers’ good rostering guide to standardise the design of rotas.3

Michael West, an organisational psychologist, led the review together with the clinical psychiatrist Denise Coia. He told The BMJ that the review deliberately focused …
Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma
Authors: Prashant Kapoor, Morie A. Gertz, Betsy Laplant, Gabriella C Malave, Eric Wolfe, Eli Muchtar, Mustaqeem A. Siddiqui, Wilson I Gonsalves, Angie R. Emanuel, Taxiarchis Kourelis, Rahma Warsame, David Dingli, Francis K. Buadi, Suzanne R. Hayman, Nelson Leung, Yi L. Hwa, Miriam A. Hobbs, Amie Fonder, Angela Dispenzieri, Martha Q. Lacy, S. Vincent Rajkumar, Shaji K. Kumar
Journal: Blood (2019)
Chronic Pneumonitis and Asbestosis
Authors: P. Gross
Journal: BMJ (1963)

National Institute of Sciences of India on the history of sciences, including medicine, of ancient India.The following quotations from my paper with S. N. Pandeyal regarding the importance of theoretical and of practical training in medical education in ancient India will, I am sure, be of interest to your readers:1. " The student who obtains his know- ledge only from books is like an ass with a burden of sandalwood, for he knows the weight but not the value thereof."" 2. "He who is versed only in books, but not skilled in practice, gets alarmed and confused, like a coward in the battlefield when confronting active disease."3. "He who is skilled in practice but is audacious and ignorant of the theory cf scU'nce, does not receive approval of thK learned men and receives capital punishment from the king."4 4. " Both these groups of persons (items 2 and 3) are lacking in dexterity and inept in the discharge of their duties, for they know only half the science and are like birds with one wing only."51am.etc.,
Allergic Reactions to Penicillin
Authors: A. I. Suchecki
Journal: BMJ (1946)

of the feet and toes were weak.Good power remained in the lowerlimb muscles.Tendon reflexes were absent in the upper and lowel limbs, save a much diminished left knee-jerk.Plantar responses were flexor.Abdominal reflexes were present and equal.There was nO sen- sory change in the upper limbs; vibration was absent in the feet.On March 7 moist sounds were still heard at both bases.The physical signs in the central nervous system were unchanged, apart from diminution to pin-prick below the elbows and mid-calf.The patient was given 2 ml. of " hepolon," intramuscularly, daily.There was increased power in the affected muscles on March 23, and consider- able improvement in the power of all affected muscle groups on May 2. The knee-jerks were just present.Summary A small epidemic of nervous diseases coinciding with an epidemic of influenza B is aescribed.It is suggested that a myeiinoclastic virus and a polioclastic virus are concerned.
EPID-09. PROGNOSTIC FACTORS IN ADULT PATIENTS WITH PRIMARY INTRACRANIAL EPENDYMOMAS: A POPULATION-BASED STUDY
Authors: Helen Yang, Abdullah Malik, Sunit Das
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Outcomes for patients with intracranial ependymoma remain poor in the current era of cancer treatment. This study aims to investigate the prognostic value of demographic and clinical variables to predict survival using the largest current database of patients with intracranial ependymoma. METHODS The Surveillance, Epidemiology and End Results (SEER) registry was queried for prognostic factors and survival outcomes of adult (≥18 years) patients diagnosed with intracranial ependymoma from 2004–2016. Survival was estimated using Kaplan Meier curves. Cox proportional hazards modeling was used to identify correlates of survival. RESULTS We identified a cohort of 229 primary intracranial ependymoma patients. The cohort showed a slight male predominance (52%) and had a mean age of 43 ± 17 years. 107 patients (47%) had WHO grade II tumors and 122 patients (53%) had WHO grade III tumors. One year survival was 85% for the entire cohort. Increasing age at diagnosis (HR: 1.05, 95% CI: 1.03–1.07) and WHO grade III tumor (HR: 4.20, 95% CI: 2.02–8.75) were independently associated with mortality after adjusting for age, sex, tumor location, extent of surgery, use of radiation therapy, and use of chemotherapy. Use of radiation therapy was associated with better one-year survival in cases of gross total resection (GTR) and subtotal resection (STR). Use of chemotherapy was not associated with mortality in the adjusted analysis (HR: 2.16, 95% CI: 0.96–4.84). CONCLUSION Our results suggest that age at diagnosis and tumor grade are independent factors associated with mortality in adult patients with intracranial ependymoma. Furthermore, use of chemotherapy was not shown to decrease mortality. These findings help guide future prognostic model making and therapeutic strategies designed by health care professionals.
Reducing the environmental impact of formula must not jeopardise women’s reproductive rights
Authors: Erin J Williams, Stephanie Maia, Rosie McNee, Kate Wishart, Clare Murphy, Ellie Cannon
Journal: BMJ (2019)

We appreciate the intent of Joffe and colleagues’ editorial to use growing concerns about the climate to persuade government to increase investment in breastfeeding support services,1 but we’re concerned it will fuel a culture in which women are ultimately held responsible for mitigating against risks—real, imagined, or predicted. …
Characteristics of Immune Checkpoint Inhibitors Trials Associated With Inclusion of Patients With HIV
Authors: Hadas Sorotsky, David Hogg, Eitan Amir, Daniel V. Araujo
Journal: JAMA Network Open (2019)

a group with intact immunological function and survival in keeping with the general population.In contrast, the exclusion of PLWH is unsupported by current data, denies patients the benefit of ICI therapy, and is ethically unjustifiable.We advocate for a broader inclusion of these patients in oncology trials.
GENE-39. CRISPRi-BASED RADIATION MODIFIER SCREEN IDENTIFIES LONG NON-CODING RNA THERAPEUTIC TARGETS IN GLIOMA
Authors: S John Liu, Martina Malatesta, Kyounghee Seo, Brian Lien, Sung Hong, Mark Koontz, David Raleigh, Erik Ullian, Daniel Lim
Journal: Neuro-Oncology (2019)

Abstract Long noncoding RNAs (lncRNAs) exhibit highly cell type-specific expression and function, making this class of transcript attractive for targeted cancer therapy. However, the vast majority of lncRNAs have not been tested as potential therapeutic targets, particularly in the context of currently used cancer therapy. Malignant glioma is rapidly fatal, and ionizing radiation is part of the current standard-of-care used to slow tumor growth in both adult and pediatric patients. Here, we used a CRISPR interference (CRISPRi) platform to systematically screen 5689 lncRNA loci in human glioblastoma (GBM) cells, identifying 467 hits that modified cell growth in the presence of clinically relevant doses of fractionated radiation. 34 of these lncRNA hits sensitized cells to radiation, and based on their expression in adult and pediatric glioma, nine of these hits were prioritized as lncRNA Glioma Radiation Sensitizers (lncGRS). Knockdown of lncGRS-1 – a primate-conserved, nuclear-enriched lncRNA – inhibited the growth and proliferation of primary adult and pediatric glioma cells, but not the viability of normal brain cells. Using human brain organoids comprised of mature neural cell types as a 3-dimensional tissue substrate to model the invasive growth of glioma, we found that antisense oligonucleotides (ASOs) targeting lncGRS-1 selectively decreased tumor growth synergistically with radiation therapy. These studies identify lncGRS-1 as a glioma-specific therapeutic target and establish a generalizable approach to rapidly identify novel therapeutic targets in the vast non-coding genome that can enhance the standard-of-care for cancer therapy.
Incidence and Risk Factors of Arterial Thromboembolism in Non-Small Cell Lung Cancer
Authors: Avi Leader, Oded Icht, Erez Batat, Uri Rozovski, Lilach Joseph, Tzippy Shochat, Daniel A Goldstein, Elizabeth Dudnik, Baruch Brenner, Pia Raanani, Galia Spectre, Hammerman Ariel, Alona Zer
Journal: Blood (2019)
The 2019 report of The Lancet Countdown on health and climate change: ensuring that the health of a child born today is not defined by a changing climate
Authors: Nick Watts, Markus Amann, Nigel Arnell, Sonja Ayeb-Karlsson, Kristine Belesova, Maxwell Boykoff, Peter Byass, Wenjia Cai, Diarmid Campbell-Lendrum, Stuart Capstick, Jonathan Chambers, Carole Dalin, Meaghan Daly, Niheer Dasandi, Michael Davies, Paul Drummond, Robert Dubrow, Kristie L Ebi, Matthew Eckelman, Paul Ekins, Luis E Escobar, Lucia Fernandez Montoya, Lucien Georgeson, Hilary Graham, Paul Haggar, Ian Hamilton, Stella Hartinger, Jeremy Hess, Ilan Kelman, Gregor Kiesewetter, Tord Kjellstrom, Dominic Kniveton, Bruno Lemke, Yang Liu, Melissa Lott, Rachel Lowe, Maquins Odhiambo Sewe, Jaime Martinez-Urtaza, Mark Maslin, Lucy McAllister, Alice McGushin, Slava Jankin Mikhaylov, James Milner, Maziar Moradi-Lakeh, Karyn Morrissey, Kris Murray, Simon Munzert, Maria Nilsson, Tara Neville, Tadj Oreszczyn, Fereidoon Owfi, Olivia Pearman, David Pencheon, Dung Phung, Steve Pye, Ruth Quinn, Mahnaz Rabbaniha, Elizabeth Robinson, Joacim Rocklöv, Jan C Semenza, Jodi Sherman, Joy Shumake-Guillemot, Meisam Tabatabaei, Jonathon Taylor, Joaquin Trinanes, Paul Wilkinson, Anthony Costello, Peng Gong, Hugh Montgomery
Journal: The Lancet (2019)
Expansion of Human Mesenchymal Stromal/Stem Cells Using Standardized Xeno-Free, Serum-Free Culture Condition
Authors: Van T. Hoang, Quynh-Mai Trinh, Phuong TM Dam, Yen-Nhi Phung, Ngan T.H. Nguyen, Hong-Hue Bui, Minh-Hang Le, Hong-Nhung Trinh, Tuyet-Anh T. Nguyen, Minh Duc Hoang, Nguyen Thanh Liem
Journal: Blood (2019)
Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Versus Matched Unrelated Donor
Authors: Michael R. Grunwald, Mei-Jie Zhang, Hany Elmariah, Mariam H Johnson, Andrew St. Martin, Asad Bashey, Javier Bolanos-Meade, Christopher Bredeson, Edward A Copelan, Biju George, Vikas Gupta, Christopher G. Kanakry, Rohtesh S. Mehta, Minoo Battiwalla, Alberto Mussetti, Ryotaro Nakamura, Taiga Nishihori, Wael Saber, Melhem Solh, Benjamin K. Tomlinson, Daniel J. Weisdorf, Mary Eapen
Journal: Blood (2019)
MiR-142-3p enhances chemosensitivity of breast cancer cells and inhibits autophagy by targeting HMGB1
Authors: Lu Liang, Jijun Fu, Siran Wang, Huiyu Cen, Lingmin Zhang, Safur Rehman Mandukhail, Lingran Du, Qianni Wu, Peiquan Zhang, Xiyong Yu
Journal: Acta Pharmaceutica Sinica B (2019)

MiR-142-3p has been reported to act as a tumor suppressor in breast cancer. However, the regulatory effect of miR-142-3p on drug resistance of breast cancer cells and its underlying mechanism remain unknown. Here, we found that miR-142-3p was significantly downregulated in the doxorubicin (DOX)-resistant MCF-7 cell line (MCF-7/DOX). MiR-142-3p overexpression increased DOX sensitivity and enhanced DOX-induced apoptosis in breast cancer cells. High-mobility group box 1 (HMGB1) is a direct functional target of miR-142-3p in breast cancer cells and miR-142-3p negatively regulated HMGB1 expression. Moreover, overexpression of HMGB1 dramatically reversed the promotion of apoptosis and inhibition of autophagy mediated by miR-142-3p up-regulation. In conclusion, miR-142-3p overexpression may inhibit autophagy and promote the drug sensitivity of breast cancer cells to DOX by targeting HMGB1. The miR-142-3p/HMGB1 axis might be a novel target to regulate the drug resistance of breast cancer patients.
Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Authors: Marion Subklewe, Anthony Stein, Roland B. Walter, Ravi Bhatia, Andrew H. Wei, David Ritchie, Veit Bücklein, Pankit Vachhani, Tian Dai, Antreas Hindoyan, Suresh Agarwal, Abraham Anderson, Sophia Khaldoyanidi, Farhad Ravandi
Journal: Blood (2019)
Long Non-Coding RNAs (lncRNAs) Are Highly Associated with Disease Characteristics and Outcome in Pediatric Acute Myeloid Leukemia - a COG and Tpaml Study
Authors: Jenny L. Smith, Rhonda E. Ries, Jason E. Farrar, Todd A. Alonzo, Robert B. Gerbing, Amanda R. Leonti, Tiffany A. Hylkema, Alan S Gamis, Richard Aplenc, Edward Anders Kolb, Cu Nguyen, Daoud Meerzaman, Timothy Junius Triche, Soheil Meshinchi
Journal: Blood (2019)
QOLP-01. THE DISCREPANCY IN GROWTH PROBLEMS BETWEEN PATIENTS WITH INTRACRANIAL GERM CELL TUMOURS ORIGINATING FROM DIFFERENT LOCATIONS
Authors: Bo Li, Youqi Li, Jiayi Wang, Xiaoguang Qiu
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Growth problems are common in patients with intracranial germ cell tumours. However, the characteristics were not fully profiled, especially when stratified by orientation. Thus, we conducted this study. METHODS Patients newly diagnosed, ≤19 years, with confirmed pathology or tumour markers elevation were included. Patients with bifocal lesions or lost to follow-up were excluded. WHO AnthroPlus software, which was developed for the global application of the WHO Reference 2007 to monitor growth in children aged 5–19 years, was used. Based on age, sex, and height, the Z-scores of height(ZSOH) were calculated. A ZSOH&lt; -1 indicates a slower physical development than that in peers, while a ZSOH &gt;1 indicates faster growth than peers. RESULTS Among the 200 included patients, 75 had primary lesions originating from the sellar/suprasellar region(S/SS), 73 from the pineal gland(PG), and 52 from the basal ganglia/thalamus region(BG/T). At initial diagnosis, the median ZSOH in S/SS was -0.66(-3.76–3.05), which was significantly lower than that in PG(0.76,-2.23–5.19) and BG/T(0.64,-3.05–5.32)(p=0.001). However, the difference in ZSOH between PG and BG/T was comparable(p=0.61). In patients with S/SS who had paired data(n=36), the median ZSOH decreased from -0.22(-3.76–3.05) at diagnosis to -1.01(-3.42–1.89) at the last follow-up(p=0.001). The median ZSOHs in PG(n=38) and BG/T(n=28) remained in the normal range at last follow-up although the changes were statistically significant(p&lt; 0.001). Linear regression analysis showed that, in S/SS, age at diagnosis(β=0.115,p=0.033), sex(β=1.337,p=0.002), radiotherapy dose(β=-0.061,p=0.007), and number of chemotherapy cycles(β=-0.177,p=0.038) were correlated with changes in median ZSOH. In BG/T, only the radiotherapy dose(β=-0.064,p=0.041) and number of chemotherapy cycles(β=-0.551,p=0.026) were correlated. However, none of the above were validated in PG. CONCLUSIONS Compared to intracranial germ cell tumours in the PG or BG/T, the growth problems in S/SS was more prominent and aggravated after treatments, especially in those with younger age, female sex, higher radiotherapy dose, and more chemotherapy cycles.
Challenging the Association of Marijuana Laws With Teen Marijuana Use
Authors: Christine L. Miller
Journal: JAMA Pediatrics (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Impact and Safety of Chimeric Antigen Receptor T Cell Therapy in Vulnerable Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Authors: Richard J Lin, Stephanie M Lobaugh, Martina Pennisi, Jason T Chan, Yakup Batlevi, Josel D Ruiz, Theresa A Elko, Molly A. Maloy, Connie Lee Batlevi, Parastoo B. Dahi, Sergio A Giralt, Elena Mead, Ariela Noy, Maria Lia Palomba, Bianca Santomasso, Craig S. Sauter, Michael Scordo, Gunjan L. Shah, Beatriz Korc-Grodzicki, Soo Jung Kim, Mari Lynne Silverberg, Chelsea A Brooklyn, Sean M. Devlin, Miguel-Angel Perales
Journal: Blood (2019)
Conventional Immunochemotherapy (R-CHOEP) Vs High-Dose Immunochemotherapy (R-MegaCHOEP) in Younger Patients with High-Risk Aggressive B-Cell Lymphoma: 10-Year Long-Term Follow-up of a German Lymphoma Alliance (GLA) Study
Authors: Fabian Frontzek, Marita Ziepert, Maike Nickelsen, Bettina Altmann, Bertram Glass, Mathias Hänel, Lorenz Truemper, Gerhard Held, Martin Bentz, Peter Borchmann, Martin H. Dreyling, Andreas Viardot, Frank P. Kroschinsky, Bernd Metzner, Annette M. Staiger, Heike Horn, German Ott, Andreas Rosenwald, Markus Loeffler, Georg Lenz, Norbert Schmitz
Journal: Blood (2019)
IMMU-06. TTFIELDS INDUCES IMMUNOGENIC CELL DEATH AND STING PATHWAY ACTIVATION THROUGH CYTOPLASMIC DOUBLE-STRANDED DNA IN GLIOBLASTOMA CELLS
Authors: Dongjiang Chen, Nagheme Thomas, Jie Ren, Son Le, Mathew Sebstian, Changwang Deng, Dan Jin, David Tran
Journal: Neuro-Oncology (2019)

Abstract OBJECTIVES Glioblastoma (GBM) is the most common and deadliest malignant brain cancer in adults. Tumor Treating Fields (TTFields) was approved in combination with adjuvant temozolomide chemotherapy for newly diagnosed GBM patients. The addition of TTFields resulted in a significant improvement in overall survival. TTFields are low-intensity alternating electric fields that are thought to disturb mitotic macromolecules’ assembly. In many patients, a transient stage of increased peritumoral edema is often observed early during TTFields treatment followed subsequently by objective radiographic responses, suggesting that a major component of therapeutic efficacy by TTFields may be an immune mediated process. We hypothesize that TTFields activate the immune system by triggering pyroptosis and type I Interferon (IFN) response. METHODS A panel of GBM cell lines were treated with TTFields at the clinically approved frequency of 200 kHz using an in vitro TTFields system. Cells were analyzed for the production of micronuclei and activation of both pyroptosis and STING pathways using immunostaining, quantitative PCR, ELISA and cytometry. RESULTS TTFields resulted in a significantly higher rate of micronuclei structures released into the cytoplasm, which were co-localized with two upstream dsDNA sensors AIM2 and cGAS. TTFields-activated micronuclei-dsDNA sensor complexes led to i) induction of pyroptotic cell death, as measured by LDH release assay, and through AIM2-recruited caspase1 and cleavage of pyroptosis-specific Gasdermin D; and ii) activation of STING pathway leading to the release of type I IFNs and pro-inflammatory cytokines downstream of the NFκB pathway. In a co-culture experiment of bone marrow cells with cells/supernatants obtained from GBM cells treated with TTFields, GBM cells depleted of AIM2 and STING failed to induce bone marrow cells. CONCLUSIONS These results provide compelling evidence that TTFields activates the innate immune system in GBM cells, and a strong rationale for combining TTFields with immune checkpoint inhibitors to create a therapeutic synergy.
FF-10101 Retains Potent Inhibitory Activities Against Resistant Mutations to FLT3 Inhibitors, Newly Identified in Random Mutagenesis Screens
Authors: Yuichi Ishikawa, Koichi Saito, Naomi Kawashima, Michie Morimoto, Hidetoshi Murao, Daisuke Terada, Takeshi Yamaura, Shinji Hagiwara, Hitoshi Kiyoi
Journal: Blood (2019)
High Court rules that 14 year old Jehovah’s Witness should have blood transfusions
Authors: Clare Dyer
Journal: BMJ (2019)

A High Court judge has given the go-ahead for doctors to give blood transfusions to a 14 year old Jehovah’s Witness boy after hearing that he would be “angry and upset” but wanted to survive.1

The teenager, referred to as CX, has survived lymphatic cancer 10 years before but now has a different form of lymphatic cancer, which is at stage IV.

He is under the care of a team of paediatric oncologists, but the court heard that the literature contained no case reports of a patient who had had both of these forms of lymphatic cancer. In the absence of guidelines or treatment protocols his doctors had consulted widely in the UK, continental Europe, and the US.

The court case was brought …
Single Cell Sequencing Reveals Heterogeneity of Gene Expression in KMT2A Rearranged Infant ALL at Relapse Compared to Diagnosis
Authors: Erin Guest, Byunggil Yoo, Rumen Kostadinov, Midhat S. Farooqi, Emily Farrow, Margaret Gibson, Neil Miller, Karina Shah, Tomi Pastinen, Patrick A. Brown
Journal: Blood (2019)
Open-Labeled, Multicenter Phase II Study of Bortezomib for Maintenance Therapy in Patients with High Risk Diffuse Large B Cell Lymphoma (DLBCL): Borma Trial from Consortium for Improving Survival of Lymphoma (CISL)
Authors: Jae-Cheol Jo, Ho Sup Lee, Cheolwon Suh, Hye Jin Kang, Won Seog Kim, HyeonSeok Eom, Inho Kim, Ho-Jin Shin, Yong Park, Won Sik Lee, Young Rok Do, Lee Gyeong-Won, Sung Yong Oh, Sung-Nam Lim, Seong Yoon Lee
Journal: Blood (2019)
Pneumocystis carinii Pneumonia
Authors: Joel Ruskin
Journal: JAMA (1968)

To the Editor:—  Since submission of our manuscript,  Compromised Host and Infection: I.Pneumocystis cariniiPneumonia (202: 1070, 1967), which detailed our experience at the Palo Alto-Stanford Hospital with five cases of pneumocystosis in immunosuppressed hosts,Pneumocystisinfection has been documented by lung biopsy premortem or by autopsy in six additional patients.1  As in the cases described in the original report, each of these six additional patients also had serious underlying disease and had received immunosuppressive drug therapy. Three of the six had reticulum cell sarcoma and were recognized in a retrospective review of autopsies of 67 patients with leukemia, lymphoma, or myeloma who had terminal nonspecific pneumonitis (personal communication, William Litrap, MD). Of the remaining three patients, one had Hodgkin's disease, another had renal transplant rejection, and the third, systemic lupus erythematosus. The diagnosis ofPneumocystispneumonia was considered in each of them prior to their death.
Phase 2 Study of Bosutinib in Japanese Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Authors: Naoto Takahashi, Itaru Matsumura, Shin Fujisawa, Kenichi Ishizawa, Takaaki ONO, Emiko Sakaida, Naohiro Sekiguchi, Yusuke Tanetsugu, Kei Fukuhara, Masayuki Ohkura, Yuichiro Koide, Masayuki Hino
Journal: Blood (2019)